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Abstract
Introduction: Presbyopia affects people from the 4th decade of life and is characterized by accommodative loss
that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological
treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of
presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address
presbyopia.
Results: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or
presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations
aimed to modify one or more factors involved in the accommodative process and have been proposed to be
instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is
involved in the achievement of the outcome and contributes to it.
Conclusion: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia
seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review
are to be considered pilot investigations as they involve either a small number of subjects or are single case series.
Complete studies are needed to confirm which will be the more effective pharmacological compound for the
treatment of presbyopia.
Keywords: Presbyopia, Ageing, Near vision, Glasses, Multifocality, Accommodation, Pharmacological therapy,
Eyedrops
Background
Presbyopia affects people from the 4th decade of life and
is characterized by accommodative loss that leads to
negative effects on vision-targeted health-related quality
of life [1]. Despite the recent advances in diagnostic
tools, the exact role of each factor (hardening of the
lens, changes in the elasticity of the lens capsule, lens di-
mension, geometry of zonular attachments and ciliary
muscle contraction) in contributing to the accommoda-
tive loss in presbyopia is still debatable. In the last few
years, a number of surgical techniques aimed to com-
pensate presbyopia have been proposed, but each one
presents some limitations, thus the most recent trends
prefer non-surgical solutions for this condition [2]. A
non-invasive pharmacological treatment providing near-
lenses independence would be a truly groundbreaking
approach in the treatment of presbyopia. The purpose of
this review is to analyze the current pharmacological so-
lutions proposed to address presbyopia.
Main text
Methods
A review on PubMed was performed analyzing all the
publications from 2005 to 2016 concerning the topic of
the pharmacological treatment of presbyopia (keywords:
presbyopia, pharmacological treatment of presbyopia,
pharmacological induction of accommodation). Only
four papers were found [3–6], underlining the difficulty
of finding a topical treatment for presbyopia. As only
few papers regarding the pharmacological treatment of
presbyopia were found to be published in peer-reviewed
journals, data was searched among those that have been
presented during international congresses or published
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in ophthalmological tabloids with an acknowledged Edi-
torial Board scientific surveillance control.
Results
One of the very few publications on the topic of the
pharmacological control of presbyopia was recently pub-
lished by Abdelkader in 2015. The publication concerns
the results of a prospective double-masked randomized
placebo-controlled clinical trial involving 48 naturally
emmetropic and presbyopic subjects aged between 43
and 56 years, which was aimed at evaluating the efficacy
of instilling carbachol 2.25% with brimonidine 0.2% eye
drops monocularly once daily for 3 months [3]. The
choice of active principles was driven by the rationale of
stimulating the parasympathetic innervation and in-
creasing depth of focus through miosis. Accommodation
induced by the parasympathomimetic was perhaps asso-
ciated with the prolongation and potentiation of these
effects by the alpha agonist. The results showed a 4-line
mean improvement of uncorrected near visual acuity
(UNVA) measured with the Jaeger scale 1 h after the in-
stillation of the drops that progressively regressed to 1
to 2 line at 10-hour, without a worsening of the uncor-
rected far visual acuity (UDVA) at any time or any ser-
ious side effects observed. Mild burning sensation was
noted by 1 subject (3.3%), dull headache was reported in
10% of the all subjects, and temporary difficulty in low
luminosity (dimness) for the first couple of weeks was
reported by 1 subject (3.3%). All the 30 subjects in the
treated group abandoned the use of near glasses, while
receiving treatment, showing satisfaction with both near
and distance vision, 12 of these patients (40%) reported
that the effect was excellent for the first 8 h and then
gradually faded.
An approach using a topically applied pharmacological
compound bilaterally was described by Renna et al. in
2016 that showed the results of a prospective pilot study
involving 14 presbyopic subjects aged 41 to 55 years [4].
The subject of the report was a study designed and per-
formed by Dr. Vejarano with a patent pending pharma-
cological combination of active principles (European
Patent Application No. EP 13 745 508.5; China Patent
Application No. PW34087KMOB) to be instilled binocu-
larly: Pilocarpine 0.247%, Phenylephrine 0.78%, Polyethy-
leneglycol 0.09%, Nepafenac 0.023%, Pheniramine
0.034%, and Naphazoline 0.003%. The rationale of choice
for this combination is because it stimulates the contrac-
tion of the ciliary body while maintaining a physiological
pupil diameter variation avoiding a worsening of visual
performance in dimness condition that would allow a
physiological image merging with clear focus at near,
intermediate, and long distance. Pilocarpine stimulates
accommodation providing both miosis and ciliary body
contraction and may improve tear production by
stimulating lacrimal gland secretion. Phenylephrine,
Nepafenac, and Pheniramine counteract ciliary muscle
spasm, vascular congestion and hyperemia induced by
pilocarpine, avoiding an excess of pupil constriction.
Naphazoline increases acetylcholine release and reduces
norepinephrine release empowering pilocarpine’s relax-
ing effect on dilator pupillae and relieving its side effects.
The lubricant effect of polyethyleneglycol protects from
the burning typically experienced from most of these
compounds and improves the tolerance for using the eye
drops. The results showed a mean UNVA improvement
by about 2 to 3 lines in each eye and binocularly from a
baseline mean of about J 3.5 to about J 1.5, with an im-
provement ≥ 3 lines until 5 h for seven patients (50% of
the total). No patient had a loss in UDVA in each eye
and binocularly. All patients enjoyed the near vision that
they had after instilling the eye drops and they would
like to have a new drop of it to continue the benefits ob-
served. No adverse effects were reported.
C. Feinbaum presented at the 2015 meeting of the
American Society of Cataract and Refractive Surgery an
investigational proprietary product (PresbiDrops, FEPA-
SAET Group) that combines a parasympathomimetic
agent with an NSAID in an oil-based formulation [7].
The rationale is the same with the eye drops studied in
the previously mentioned study by Abdekalder. Fein-
baum’s study analyzed 81 patients from 42 to 74 years.
Ten eyes were pseudophakic, four eyes had cataract, ten
eyes were postLASIK or PRK, and 57 were presbyopic
without lens opacity. Spherical refraction for the group
ranged from −0.75 D to +1.50 D and astigmatism was
up to −1.75 D. There were claimed significant improve-
ments in both mean UDVA (from 0.932 to 1.141) and
UNVA (0.356 to 0.649). The pseudophakic group
showed significant improvements in both UNVA and
UDVA, while presbyopic patients who were postrefrac-
tive surgery maintained 20/20 distance UDVA and had a
significant improvement in UNVA from 0.4 to 0.7.
Three-fourths of the patients experienced no adverse re-
action. Four patients developed nausea immediately after
instillation that quickly resolved, and four patients devel-
oped headache that gradually disappeared (duration 10–
15 min). Local adverse events included two cases each of
dryness or burning, four cases of stinging, and four cases
of blurry distance vision, all of which dissipated over
5 min.
The approach proposed by the company, Presbyopia
Therapies, to address presbyopia is a drop known as Li-
quid Vision, binocularly instilled, that has a pure miotic
effect without stimulation of accommodation [8]. The
rationale is to produce a pinhole effect avoiding the cil-
iary muscle contraction that would cause a miopic shift
worsening far vision. The exact constituents of the drop
are proprietary in nature. The company claims a rapid
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effect on the pupil that leads a stable pupil diameter of
approximately 1.6 mm, with a duration of action of ap-
proximately 8 h. In the preliminary trials performed by
Dr. Castillejos in Tijuana, Mexico, which included pa-
tients ranging in age from 46 to 63, near visual acuity
improved 3 to 7 lines on the Jaeger scale without com-
promising distance vision. Patients have reported con-
junctival injection upon instillation as well as some
stinging. Some minimal dimming indoors is possible for
the first few days of use, although patients describe this
effect as limited to those first few days. A phase 2 U.S.
clinical trial is in the planning stage.
The J. Benozzi method uses pilocarpine 1% and diclofe-
nac 0.1% [5]. The rationale is the same as discussed for the
eye drops containing a parasympathomimetic with a non-
steroidal anti-inflammatory drug (NSAID). Benozzi treated
100 patients between 45 and 50 years with his method for
5 years. The author reported that all of patients undertaking
the treatment under his survey were showing a near vision
of J1 and a far vision of 20/20 instilling the eye drop at 6-
hour intervals, daily. Twenty subjects had ocular burning
and discomfort after drop instillation, with one of them
abandoning treatment because of that. Four other patients
abandoned the pharmacological treatment because they
feared chronic drop instillation.
Presbyeyedrops© is another eye drop based on a com-
bination of two parasympathomimetics and a NSAID [9].
It was used in a pilot study involving 15 eyes and the au-
thors claimed that they had improvements of UDVA from
0.8 to 1.0 and of UNVA from 0.54 to 0.8. One patient re-
ported nausea after the instillation, one patient reported
dryness, and one patient had a burning feeling.
Another eye drop that stimulates the ciliary muscle to
accommodate and constricts the pupil is based on the
proprietary components of PresbyPlus: two parasympa-
thomimetics and one parasympatholytic [10]. These eye
drops were instilled bilaterally twice a day in a clinical
trial that showed that 90% of subjects could see J4 to J1
within 1 year without adverse reactions.
A completely different approach for the pharmaco-
logical treatment of presbyopia consists in targeting the
crystalline lens. A lipoic acid patented derivative drop was
developed by Encore Vision to reduce crystalline protein
disulfide bonds, aiming to soften the lens, thus preserving
the natural shape-changing ability in order to restore the
accommodative amplitude [6]. In 2016, the company
begun a 90-day phase 1/2 clinical trial including 66 pres-
byopic subjects between the ages of 45 and 55 years.
Conclusion
The pharmacological control of presbyopia is a very at-
tractive option for those affected by presbyopia and in-
creasing near vision spectacle dependence. Despite the
interest on this topic, there are only a few publications
available, all from the recent years. As a non-invasive so-
lution for addressing this problem, pharmacological con-
trol of presbyopia would meet all of the established
criteria for the severity of presbyopia in different sub-
jects. The pharmacological compounds analyzed in this
review aim to target one or more factors involved in the
near vision process. Most of the topical products use
pharmacological compounds, including a combination of
different drugs. Therefore, it remains unclear how much
each of the drug in the final combined form is involved
in the outcome and contributes to it.
The pharmacological control of presbyopia presents it-
self, on this review, as a possible and very attractive al-
ternative for presbyopic patients. The studies mentioned
in this review are to be considered pilot investigations as
they involve either a small number of subjects or are sin-
gle case series. Moreover, reports presented at inter-
national meetings and published on scientific tabloids,
are not peer-reviewed. Due to its large interest and po-
tential general application, further and more complete
studies are needed to confirm which will be the more ef-
fective pharmacological drug for presbyopia treatment.
Despite the limitations of the papers reviewed, such pre-
liminary results speak to the possibility of a pharmaceut-
ical treatment for presbyopia. Patient studies are very
expensive and probably limited the scope of these inves-
tigations (ad hoc patients and private funds).
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